BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36857998)

  • 21. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
    Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
    Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer.
    Vrede SW; Kasius J; Bulten J; Teerenstra S; Huvila J; Colas E; Gil-Moreno A; Boll D; Vos MC; van Altena AM; Asberger J; Sweegers S; van Weelden WJ; van der Putten LJM; Amant F; Visser NCM; Snijders MPLM; Küsters-Vandevelde HVN; Kruitwagen R; Matias-Guiu X; Weinberger V; Reijnen C; Pijnenborg JMA
    JAMA Netw Open; 2022 Dec; 5(12):e2247372. PubMed ID: 36525269
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    De Leo A; de Biase D; Lenzi J; Barbero G; Turchetti D; Grillini M; Ravegnini G; Angelini S; Zamagni C; Coluccelli S; Dondi G; De Iaco P; Perrone AM; Tallini G; Santini D; Ceccarelli C
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted mutation analysis of endometrial clear cell carcinoma.
    Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?
    Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Vergoni F; Amunni G; Fambrini M; Petraglia F; Noci I; Pillozzi S
    Reprod Sci; 2020 Feb; 27(2):592-598. PubMed ID: 32046431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
    Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
    Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
    Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Surface epithelial slackening" pattern in endometrioid carcinoma: A morphological feature for differentiating the POLE mutation-subtype from the no specific molecular profile subtype.
    Kitazono I; Akahane T; Yokoyama S; Kobayashi Y; Togami S; Yanazume S; Tasaki T; Noguchi H; Tabata K; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2023 Jul; 247():154563. PubMed ID: 37229919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
    Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
    Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
    Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
    Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
    Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
    Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
    Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-stop molecular classification of endometrial carcinoma using comprehensive next-generation sequencing.
    Li Y; Chen R; Yuan M; Wang D; Fu C; Chen R; Lei C; Zhou Q
    Int J Cancer; 2022 Dec; 151(11):1969-1977. PubMed ID: 36036365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.